In the last 20 years, several incretin-based therapies, namely glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs, incretin mimetics) and dipeptidyl peptidase-4 inhibitors (DPP-4is, incretin enhancers), have been developed for people with type 2 diabetes [1]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.